UK deep-tech startup StandardX has raised £10 million in seed funding to build what it says will be the world’s first scalable isotope refinery, targeting a critical supply bottleneck in cancer care while laying the groundwork for future fusion energy.

 

The round was led by European deep-tech investors Vsquared Ventures and East X Ventures, with participation from firstminute capital, UKI2S, Brevan Howard Macro Venture and Geometry.

 

StandardX says its accelerator-based refinery is designed to manufacture a broad portfolio of rare isotopes at commercial scale, replacing today’s fragmented network of ageing and highly specialised production facilities.

 

“Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply... So we're building the platform the world needs to address this,” says Richard Pearson, CEO, StandardX.

 

The company will initially focus on medical isotopes used in cancer diagnosis and treatment, serving both hospitals and pharmaceutical developers working on next-generation therapies.

 

StandardX plans to supply its first isotopes to a medical research partner in 2027, with industrial-scale production targeted from 2029.

 

The supply crunch is particularly acute in oncology. StandardX points to NHS data showing that just 69.6% of patients received treatment within 62 days of an urgent referral in May 2026, compared with the NHS target of 85%. The company also says shortages of isotopes needed for emerging cancer therapies, including targeted alpha therapies, have contributed to clinical trials being delayed or paused in the UK, Europe and elsewhere.

 

The company’s technology is intended to address the underlying production constraints by using a standardised accelerator system that can be deployed close to demand. StandardX says each system will be capable of producing its full isotope portfolio, enabling a more distributed supply model.

 

StandardX’s ambitions extend beyond medicine.

 

The same accelerator platform is designed eventually to produce isotopes for advanced energy applications, including tritium — a scarce hydrogen isotope regarded as a key fuel for some fusion-energy systems.

 

StandardX says only around 25kg of tritium exists globally today, while tens of kilograms could be required to operate a single fusion power plant for a year. The company has already signed agreements with leading fusion developers to manufacture tritium.

 

Founded in 2025 by nuclear engineers Richard Pearson and Ross Allen, StandardX has assembled a 15-person team with experience spanning SpaceX, The London Clinic, Oxford University, Cambridge University, Fermilab and the UK Atomic Energy Authority.

 

The new funding will be used to expand the team, secure an industrial site in London and accelerate development of the company’s first accelerator-based isotope refinery.

 

Richard said: “Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply. Shortages are most acute in cancer medicine, already impacting patients today, and stalling progress in the development of next-generation treatments. This problem will only get worse, with new cancer cases projected to increase 67% by 2050. So we're building the platform the world needs to address this.”

 

Ross added: “StandardX began with a problem: isotope supply limited by legacy infrastructure. This raise moves us from concept into engineering, physics into hardware, and conversations into delivery. Our immediate priority is our industrial site in London, where we will deploy our first isotope refinery system and work closely with clinicians and researchers to start building a reliable supply chain.”

 

The company expects the new funding to take its technology from engineering and design into pilot production, with initial medical isotope distribution planned for 2027.

 

Lise Rechsteiner, General Partner at Vsquared: “Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment. 

 

"We believe it can become critical infrastructure for the next era of radiopharma and Richard and Ross have the rare technical expertise and ambition to build it. Being located in London puts StandardX at the heart of one of Europe’s leading ecosystems for cancer research and clinical trials.”

 

Theodore Mollinger, General Partner at EastX: “StandardX is tackling a supply problem that matters enormously today in medicine, while building a platform that could become critical infrastructure for fusion tomorrow.

 

"What makes the opportunity particularly compelling is the asymmetry: StandardX can build a valuable isotope business without relying on fusion timelines, but if fusion scales, tritium could become one of the defining industrial bottlenecks of the sector. With only a tiny global inventory today and substantial quantities ultimately required to fuel commercial fusion systems, we believe StandardX has the potential to play a critical role in securing that supply.”